CompanyGraph
Asymchem Laboratories (Tianjin) Co., Ltd.
002821 · SZSE · China
asymchem.com.cnFinancials as of FY2025
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $7.57B, above the global median of $1.15B
- FinancialsAltman Z-Score 13.24: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.93%Above 5Y avg (0.59%)
Annual Rate
CNY 1.30Paid annual
Payout Ratio
44.4%Sustainable
Last Ex-Dividend
Jun 26, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
50.55BCNY7.57B · vs all stocks (USD)
Trailing P/E
52.38xvs Biotechnology peers
Revenue (TTM)
7.09BCNY1.06B · vs all stocks (USD)
Profit Margin
14.61%vs Biotechnology peers
Beta
0.1940xvs all stocks
52-Week Change
33.77%vs all stocks
Market Capitalization
50.55BCNY7.57B · vs all stocks (USD)
Enterprise Value
48.32BCNY7.23B · vs all stocks (USD)
Trailing P/E
52.38xvs Biotechnology peers
Forward P/E
30.05xvs Biotechnology peers
Price to Sales (TTM)
7.84xvs Biotechnology peers
Price to Book (MRQ)
3.08xvs Biotechnology peers
Enterprise to Revenue
6.82xvs Biotechnology peers
Enterprise to EBITDA
28.20xvs Biotechnology peers
Gross Margin
41.52%vs Biotechnology peers
Profit Margin
14.61%vs Biotechnology peers
Operating Margin
17.49%vs Biotechnology peers
Return on Assets (TTM)
3.63%vs Biotechnology peers
Return on Equity (TTM)
5.90%vs Biotechnology peers
Revenue (TTM)
7.09BCNY1.06B · vs all stocks (USD)
Revenue per Share (TTM)
20.02CNYUpdated Oct 22, 2026Quarterly Revenue Growth
9.60%vs Biotechnology peers
Gross Profit (TTM)
2.87BCNY430.36M · vs all stocks (USD)
EBITDA (TTM)
1.96BCNY293.70M · vs all stocks (USD)
Net Income (TTM)
1.04BCNY155.07M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-25.70%vs Biotechnology peers
Operating Cash Flow (TTM)
1.53BCNY228.83M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-607.50MCNY-90.97M · vs all stocks (USD)
Trailing Annual Dividend Rate
1.30CNYUpdated Oct 22, 2026Trailing Annual Dividend Yield
0.93%vs all stocks
5-Year Average Dividend Yield
0.59%vs all stocks
Payout Ratio
44.37%vs Biotechnology peers
Minority Interest (Equity)
11.04MCNYFY2025 · Dec 31, 2025Revenue
6.67BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
3.87BCNYFY2025 · Dec 31, 2025Gross Profit
2.80BCNYFY2025 · Dec 31, 2025Operating Income
1.25BCNY187.79M · vs all stocks (USD)
Pre-tax Income
1.29BCNYFY2025 · Dec 31, 2025Income Tax Expense
159.74MCNYFY2025 · Dec 31, 2025Net Income
1.13BCNYFY2025 · Dec 31, 2025EBIT
1.30BCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
1.96BCNYFY2025 · Dec 31, 2025Research & Development
593.26MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
260.93MCNYFY2025 · Dec 31, 2025Other Operating Expenses
63.39MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
202.97MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
12.75MCNYFY2025 · Dec 31, 2025EPS (Basic)
3.16CNYFY2025 · Dec 31, 2025EPS (Diluted)
3.16CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
358.41MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
358.41MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
1.13BCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
5.93MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
518.17MCNYFY2025 · Dec 31, 2025Free Cash Flow
-752.15MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
3.40BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
1.13BCNYFY2025 · Dec 31, 2025Other Non-cash Items
43.20MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-265.55MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-386.11MCNYFY2025 · Dec 31, 2025Capital Expenditures
-1.27BCNYFY2025 · Dec 31, 2025Purchase of Investments
-11.53BCNYFY2025 · Dec 31, 2025Sale of Investments
12.15BCNYFY2025 · Dec 31, 2025Other Investing Activity
14.16MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-633.20MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-395.07MCNYFY2025 · Dec 31, 2025Other Financing Charges
50.23MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-344.83MCNYFY2025 · Dec 31, 2025Shares Outstanding
360.78MSharesUpdated Oct 22, 2026Float Shares
217.44MSharesUpdated Oct 22, 2026% Held by Insiders
41.03%vs all stocks
% Held by Institutions
24.67%vs all stocks
Total Cash (MRQ)
6.61BCNY989.24M · vs all stocks (USD)
Total Cash per Share (MRQ)
18.58CNYUpdated Oct 22, 2026Total Debt (MRQ)
346.61MCNY51.90M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0195xvs Biotechnology peers
Current Ratio (MRQ)
4.56xvs Biotechnology peers
Book Value per Share (MRQ)
49.89CNYUpdated Oct 22, 2026Total Assets
20.28BCNY3.04B · vs all stocks (USD)
Total Current Assets
11.51BCNYFY2025 · Dec 31, 2025Total Liabilities
2.63BCNYFY2025 · Dec 31, 2025Total Non-current Assets
8.77BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
662.84MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.97BCNYFY2025 · Dec 31, 2025Cash
5.78BCNYFY2025 · Dec 31, 2025Cash Equivalents
543.99MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
6.32BCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.12BCNYFY2025 · Dec 31, 2025Accounts Receivable
1.95BCNYFY2025 · Dec 31, 2025Inventory
1.47BCNYFY2025 · Dec 31, 2025Accounts Payable
589.04MCNYFY2025 · Dec 31, 2025Short-term Debt
52.71MCNYFY2025 · Dec 31, 2025Other Current Liabilities
26.95KCNYFY2025 · Dec 31, 2025Long-term Debt
256.47MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
27.56KCNYFY2025 · Dec 31, 2025Common Stock (Book)
360.56MCNYFY2025 · Dec 31, 2025Retained Earnings
8.82BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
17.65BCNY2.64B · vs all stocks (USD)
Treasury Stock
838.45MCNYFY2025 · Dec 31, 202552-Week Low
88.46CNYUpdated Oct 22, 202652-Week High
200.00CNYUpdated Oct 22, 202652-Week Change
33.77%vs all stocks
Beta
0.1940xvs all stocks
50-Day MA
174.54CNYUpdated Oct 22, 2026200-Day MA
135.10CNYUpdated Oct 22, 2026Avg 10-Day Volume
8.01MSharesUpdated Oct 22, 2026Avg 30-Day Volume
8.57MSharesUpdated Oct 22, 2026Diluted EPS (TTM)
2.93CNYUpdated Oct 22, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 13.24: safe zoneNotable
Altman Z-Score: 13.24
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $7.57B, above the global median of $1.15BNotable
Market cap (USD): 7,569,319,752.474Global Median: 1,150,342,212.262
Revenue is $1.06B, above the global median of $559.35MNotable
Revenue (USD): 1,061,463,993.631Global Median: 559,350,010.583
Companies that share the same coordination system — how they create, deliver, or capture value.
Spyre Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
ALK-Abello A/S
Tier 1ProductionApproval-Gated PipelineRule
Abivax SA
Tier 1ProductionApproval-Gated PipelineRule
Ionis Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Praxis Precision Medicines Inc.
Tier 1ProductionApproval-Gated PipelineRule
Grifols, S.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Demant A/S
Tier 1ProductionApproval-Gated PipelineFlowRule
InnoCare Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Glenmark Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Amneal Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
AJ Bell plc
1 interpretationHigh Retained Earnings With Profitability And Equity
Alamo Group Inc.
1 interpretationHigh Retained Earnings With Profitability And Equity
Movado Group Inc.
1 interpretationHigh Retained Earnings With Profitability And Equity